Research Areas

An FDA rejection, Takeda restructuring, Trump initiatives and more lead the news this week.

Faster drug discovery depends on both speed and data quality — a new mass spectrometry technology is helping researchers achieve both.

AI has moved beyond buzzword status to become a core technology in pharmaceutical R&D.

With blockbuster status secured, GLP-1 therapies face new questions about efficacy, delivery, and their role in treating multiple chronic diseases.

Embracing informatics solutions lets researchers effectively manage data, collaboration, and the growing complexity of modern research.

Papzimeos is the first FDA-approved therapy for recurrent respiratory papillomatosis, a rare HPV-driven disease that has long forced patients into repeated surgeries.

Explore the trends, tools, and challenges shaping how scientists screen drug candidates to advance therapeutic discovery.

Activace platform enables targeted, genome-wide profiling of unmethylated DNA regions, providing a comprehensive view of the epigenome that can be scaled to the study of large patient cohorts

Advances in allosteric inhibitors may offer a new standard of care that balances potent disease control with better tolerability and convenience.

LGC Standards reveals new 13C-labelled PFAS mixtures and single solutions to support laboratories using EPA Method 1633.